GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merus NV (NAS:MRUS) » Definitions » Altman Z-Score

Merus NV (Merus NV) Altman Z-Score : 13.43 (As of Apr. 25, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Merus NV Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Good Sign:

Altman Z-score of 12.38 is strong.

Merus NV has a Altman Z-Score of 13.43, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Merus NV's Altman Z-Score or its related term are showing as below:

MRUS' s Altman Z-Score Range Over the Past 10 Years
Min: -3.68   Med: 0.67   Max: 12.38
Current: 12.38

During the past 12 years, Merus NV's highest Altman Z-Score was 12.38. The lowest was -3.68. And the median was 0.67.


Merus NV Altman Z-Score Historical Data

The historical data trend for Merus NV's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus NV Altman Z-Score Chart

Merus NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 -0.04 5.03 0.79 7.10

Merus NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.79 0.89 4.06 6.05 7.10

Competitive Comparison of Merus NV's Altman Z-Score

For the Biotechnology subindustry, Merus NV's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merus NV's Altman Z-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Merus NV's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Merus NV's Altman Z-Score falls into.



Merus NV Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Merus NV's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.658+1.4*-1.6533+3.3*-0.3331+0.6*26.5941+1.0*0.0965
=13.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $455.49 Mil.
Total Current Assets was $368.81 Mil.
Total Current Liabilities was $69.09 Mil.
Retained Earnings was $-753.06 Mil.
Pre-Tax Income was -59.116 + -21.894 + -30.539 + -40.198 = $-151.75 Mil.
Interest Expense was 0 + 0 + 0 + 0 = $0.00 Mil.
Revenue was 8.939 + 11.033 + 10.476 + 13.499 = $43.95 Mil.
Market Cap (Today) was $2,636.83 Mil.
Total Liabilities was $99.15 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(368.814 - 69.089)/455.494
=0.658

X2=Retained Earnings/Total Assets
=-753.061/455.494
=-1.6533

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-151.747 - 0)/455.494
=-0.3331

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=2636.830/99.151
=26.5941

X5=Revenue/Total Assets
=43.947/455.494
=0.0965

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Merus NV has a Altman Z-Score of 13.43 indicating it is in Safe Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Merus NV  (NAS:MRUS) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Merus NV Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Merus NV's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Merus NV (Merus NV) Business Description

Traded in Other Exchanges
Address
Uppsalalaan 17, Utrecht, NLD, 3584 CT
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Executives
Harry Shuman officer: Chief Accounting Officer C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Peter B. Silverman officer: EVP & General Counsel C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Sven Ante Lundberg director, officer: President, CEO & PFO C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Kruif John De officer: Chief Technology Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM
Paolo Pucci director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Len Kanavy director C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Maxine Gowen director
Anand Mehra director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Victor Sandor director C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Mark T Iwicki director 84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Gregory D Perry director C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Geuijen Cecile A W officer: SVP & Chief Scientific Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584CM
Andrew Joe officer: SVP, CMO C/O MERUS N.V., VALELAAN 62, UTRECHT P7 3584 CM
Mark Throsby officer: EVP & Chief Scientific Officer C/O MERUS N.V., YALELAAN 62, UTRECHT P7 3584 CM